Medical Distribution — industry outlook

Period: 2026-08-30 to 2026-09-20
Events: 6
Generated: 2026-09-20T06:30:00.003Z

Financial Guidance and Capital Allocation

Majority of the sector projects double-digit EPS growth for Fiscal Year 2027, with specific targets ranging from 13% to 15% for McKesson (MCK) and Cardinal Health (CAH), while Cencora (COR) anticipates a "good year" with momentum slightly below the previous year's upside. McKesson (MCK) raised its FY2027 EPS guidance to $44.20–$45.00, while Cardinal Health (CAH) expects 15%–18% operating income growth and 13%–15% EPS growth, exceeding its long-term targets. MCK plans $5 billion in buybacks for FY2027 (half already executed) and a 15% dividend increase; CAH targets at least $1 billion in buybacks and $700 million in capex; Cencora (COR) commits to growing dividends and opportunistic repurchases while prioritizing debt reduction; Henry Schein (HSIC) targets $200 million in net operating income improvement over two to three years and aims for ~$600 million in annual free cash flow.

Specialty Distribution and Growth Engines

All major players (MCK, CAH, COR) identify specialty pharma as the primary growth engine, driven by aging demographics, oncology, and retina sectors. McKesson (MCK) maintains AOP growth guidance of 13.5%–17.5% for Oncology and Multi-Specialty (O&M) and 11%–15% for RxTS; Cardinal Health (CAH) projects "closer to double-digit" specialty growth in FY2027 after a high-impact FY26; Cencora (COR) expects Area of Interest growth of 14.5%–15.5% to continue into FY2027 and beyond. AOP growth for McKesson's (MCK) North America Pharmaceuticals is raised to the high end of the 5.5%–9.5% range. Cardinal Health (CAH) forecasts generics volume growth of 2%–3% for FY2027, with significant Loss of Exclusivity (LOE) benefits expected in 2028–2029. Henry Schein (HSIC) targets 3%–4% sustained growth in consumables and high single-digit growth in its ~$400 million Home Solutions business.

Management Services Organizations and Provider Networks

Companies are aggressively expanding MSO networks to capture the "beginning, middle, and end" of care, focusing on oncology, urology, and gastroenterology. McKesson (MCK) aims to expand its US Oncology Network to 3,400 providers and applies a similar playbook to its 200+ provider PRISM network in retina; Cardinal Health (CAH) is integrating MSO acquisitions like Solaris and Navista to target the 80%–90% of unaffiliated physicians in GI/Urology; Cencora (COR) projects its MSO segment could contribute double digits (10%) to profitability by FY2027 and considers breaking out MSO metrics for transparency. Henry Schein (HSIC) emphasizes disciplined M&A focused on "tuck-ins" that drive ROIC and organic growth, moving away from the predecessor's heavy M&A approach.

Therapeutics Trends: GLP-1s, Biosimilars, and Theranostics

Managers across the sector (MCK, CAH, COR) view GLP-1s and biosimilars as constructive tailwinds, though with different revenue impacts. McKesson (MCK) anticipates additive revenue from GLP-1 orals without cannibalizing injectables (currently ~11% of RxTS revenue) and expects strong momentum from the Medicare BIDG program; Cardinal Health (CAH) views biosimilars as an "early innings" story that may mature in FY28–FY29, while noting LOE cycles will drive generic profitability; Cencora (COR) sees the Part B biosimilar transition as a "sweet spot" and "disproportionate tailwind." Cardinal Health (CAH) targets a 20% CAGR in Theranostics revenue to reach a two-thirds mix of nuclear revenue by FY2028; Henry Schein (HSIC) faces softness in respiratory testing (~15% of Medical segment) but expects digital equipment volume growth, albeit with ASP pressure.

Regulatory Environment and Policy Risks

Companies generally express high confidence in protecting provider economics, though they disagree on specific IRA implementation impacts. McKesson (MCK) and Cencora (COR) anticipate no material disruption to community provider economics from IRA Part B in 2028, advocating for a "GLOBE model" or manufacturer rebates to CMS to maintain physician margins; however, Cardinal Health (CAH) expects manufacturer negotiations on WAC adjustments to be necessary to compensate for service impacts. While MCK (MCK) and CAH (CAH) view 340B volume shifts as manageable or customer-level mix changes, Cencora (COR) acknowledges the need to monitor 340B proposals closely. All firms (MCK, CAH, COR) agree that significant pricing pressure will remain in Part D (oral products) rather than Part B (infusion/specialty).

M&A Strategy and Operational Execution

M&A strategies are converging on "disciplined," bolt-on acquisitions to fill white space or add density rather than large-scale consolidations. McKesson (MCK) is integrating Precision Medicine Group (PMG) to complement its oncology assets, targeting EPS accretion; Cardinal Health (CAH) and Cencora (COR) are prioritizing "tuck-in" MSO deals and at-home acquisitions (e.g., Cardinal's Strive, Cencora's One Oncology) to expand provider bases. Henry Schein (HSIC) notes a shift to a more disciplined M&A algorithm focused on ROIC and organic growth drivers. McKesson (MCK) and Cardinal Health (CAH) both view their recent large acquisitions as fully integrated or nearing full integration impacts, with CAH noting Solaris will lap into results in Q2 FY2027.

Macro, Supply Chain, and Competitive Dynamics

Firms report minimal tariff exposure (MCK) or mitigation via pass-throughs (CAH, HSIC), with concerns focused on commodity volatility and geopolitical conflicts. McKesson (MCK) cites minimal tariff exposure as most products are US-manufactured; Cardinal Health (CAH) and Henry Schein (HSIC) monitor oil and raw material costs (e.g., Iran conflict) and anticipate pricing pressures to be difficult to sustain beyond the current year. Cardinal Health (CAH) and Cencora (COR) report "constructive" but normalized demand trends compared to the "outsized" growth of FY26. Henry Schein (HSIC) highlights a shift toward private label products growing at 2x the rate of third-party brands to improve margins, while MCK (MCK) sees no observable shifts in 340B volume flow despite policy proposals.